Mendoza ÁS, Alonso-Moctezuma A, Salgado-Chavarría F

Language: Spanish
References: 40
Page: 32-37
PDF size: 177.82 Kb.

ABSTRACT

Ameloblastoma is a progressively growing benign intraosseous epithelial odontogenic odontogenic neoplasm characterized by local invasion and a tendency to recur if not adequately removed. Although the pathogenesis of ameloblastoma is controversial, treatment of this pathology varies from simple enucleation and curettage to en bloc resection. This article presents an overview of the molecular pathogenesis, the history of ameloblastoma, and a perspective of relevance according to the molecular advances that have occurred in the research of this tumor. A literature search was performed in the PubMed and EMBASE databases using the keywords: ameloblastoma, history, molecular tools, pathogenesis, odontogenic tumor, articles were collected from the literature in English, reporting on molecular tools and the history of ameloblastoma. Although the pathogenesis of ameloblastoma is controversial, several authors have invoked numerous theories to elucidate the development and behavior of these tumors. Recently, studies have increasingly focused on the molecular aspects of ameloblastoma pathogenesis to identify potential therapeutic targets. However, the molecular background of ameloblastoma development remains unclear. The presence or absence of mutations correlates with several clinicopathologic features, including location, age at diagnosis, histology, and prognosis. Further studies are needed to verify these theories.

REFERENCES

1. Vered M, Wright JM. Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Odontogenic and Maxillofacial Bone Tumours. Head Neck Pathol. 2022; 16 (1): 63-75. doi: 10.1007/s12105-021-01404-7.

2. Neville. Oral and maxillofacial pathology. Elsevier; 2016.

3. Rajendra Santosh AB, Ogle OE. Odontogenic tumors. Dent Clin North Am. 2020; 64 (1): 121-138.

4. Brown NA, Betz BL. Ameloblastoma: a review of recent molecular pathogenetic discoveries. Biomark Cancer. 2015; 7s2: BIC.S29329.

5. Philipsen HP, Reichart PA. Classification of odontogenic tumours. A historical review. J Oral Pathol Med. 2006; 35 (9): 525-529.

6. Sutton JB. Odontomes. Am J Dent Sci. 1888; 21 (9): 405.

7. Lucas RB. Pathology of tumours of the oral tissues. Churchill Livingstone; 1984.

8. Pindborg J. A calcifying epithelial odontogenic tumor. Cancer. 1958; 11 (4): 838-843.

9. Kramer IR. International histological classification of tumours. Histol Typing Odontogenic Tumours. 1992.

10. Wright JM, Vered M. Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Odontogenic and Maxillofacial Bone Tumors. Head Neck Pathol. 2017; 11 (1): 68-77.

11. Thoma KH, Goldman HM. Odontogenic tumors: A classification based on observations of the epithelial, mesenchymal, and mixed varieties. Am J Pathol. 1946; 22 (3): 433.

12. Jacobson JK. The odontomas: two case reports. Am J Orthod Dentofacial Orthop. 1946; 32 (2): A147-152.

13. Gianní E. Primary neoplasms of the jaw. Electron microscopic aspects and enzymo-histotopicochemical studies. Minerva Stomatol. 1965; 14 (7): 392.

14. Knapp RH, Wick MR, Scheithauer BW, Unni KK. Adamantinoma of bone. Virchows Arch A. 1982; 398 (1): 75-86.

15. Vedtofte P, Dabelsteen E. Receptors for the lectins wheat germ: Ricinus Communis I and Soybean in Ameloblastomas and Normal Oral Mucosa. Acta Pathol Microbiol Scand [A]. 1981; 89 (1-6): 439-449.

16. Sauk J, Cocking-Johnson D, Warings M. Identification of basement membrane components and intermediate filaments in calcifying epithelial odontogenic tumors. J Oral Pathol Med. 1985; 14 (2): 133-140.

17. Kreicbergs A, Silvfersward C, Tribukait B. Flow DNA analysis of primary bone tumors. Relationship between cellular DNA content and histopathologic classification. Cancer. 1984; 53 (1): 129-136.

18. Luo W, Roop D, Lau E, Melrose R, Mostofi R, Stenman G et al. In situ hybridization analysis of keratin gene expression in human ameloblastomas. J Oral Pathol Med. 1988; 17 (9-10): 534-540.

19. Heikinheimo K, Sandberg M, Happonen R, Virtanen I, Bosch F. Cytoskeletal gene expression in normal and neoplastic human odontogenic epithelia. Lab Investig J Tech Methods Pathol. 1991; 65 (6): 688-701.

20. Heikinheimo K, Voutilainen R, Happonen R, Miettinen P. EGF receptor and its ligands, EGF and TGF-alpha, in developing and neoplastic human odontogenic tissues. Int J Dev Biol. 1993; 37 (3): 387-396.

21. Kumamoto H, Mryazawa M, Ooya K. Characterization of novel monoclonal antibodies raised against formalin-fixed, paraffin-embedded human ameloblastoma. J Oral Pathol Med. 1996; 25 (9): 484-490.

22. Carinci F, Francioso F, Rubini C, Fioroni M, Tosi L, Pezzetti F et al. Genetic portrait of malignant granular cell odontogenic tumour. Oral Oncol. 2003; 39 (1): 69-77.

23. Crincoli V, Scivetti M, Di MB, Lucchese A, Favia G. Complex odontoma: confocal laser scanning microscopy analysis of a case. Minerva Stomatol. 2006; 55 (5): 315-319.

24. García-Muñoz A, Rodríguez MA, Bologna-Molina R, Cázares-Raga FE, Hernández-Hernández FC, Farfán-Morales JE et al. The orosomucoid 1 protein (α1 acid glycoprotein) is overexpressed in odontogenic myxoma. Proteome Sci. 2012; 10 (1): 49.

25. García-Muñoz A, Bologna-Molina R, Aldape-Barrios B, Licéaga-Escalera C, Montoya-Pérez LA, Rodríguez MA. Identification of proteins with increased levels in ameloblastic carcinoma. J Oral Maxillofac Surg. 2014; 72 (6): 1183-1196.

26. Vasconcelos RC, de Oliveira Moura JMB, Lacerda Brasileiro Junior V, da Silveira ÉJD, de Souza LB. Immunohistochemical expression of GLUT-1, GLUT-3, and carbonic anhydrase IX in benign odontogenic lesions. J Oral Pathol Med. 2016; 45 (9): 712-717.

27. Jernvall J, Thesleff I. Reiterative signaling and patterning during mammalian tooth morphogenesis. Mech Dev. 2000; 92 (1): 19-29.

28. Nagi R, Sahu S, Rakesh N. Molecular and genetic aspects in the etiopathogenesis of ameloblastoma: An update. J Oral Maxillofac Pathol JOMFP. 2016; 20 (3): 497.

29. Brown NA, Betz BL. Ameloblastoma: A Review of Recent Molecular Pathogenetic Discoveries. Biomark Cancer. 2015; 7 (Suppl 2): 19-24.

30. Mishra P, Panda A, Bandyopadhyay A, Kumar H, Mohiddin G. Sonic hedgehog signalling pathway and ameloblastoma - a review. J Clin Diagn Res. 2015; 9: ZE10-13.

31. Sweeney RT, McClary AC, Myers BR, Biscocho J, Neahring L, Kwei KA et al. Identification of recurrent SMO and BRAF mutations in ameloblastomas. Nat Genet. 2014; 46: 722-725.

32. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417: 949-954.

33. Niault TS, Baccarini M. Targets of raf in tumorigenesis. Carcinogenesis. 2010; 31: 1165-1174.

34. Kurppa KJ, Caton J, Morgan PR, Ristimaki A, Ruhin B, Kellokoski J et al. High frequency of BRAF V600E mutations in ameloblastoma. J Pathol. 2014; 232: 492-498.

35. Wright JM, Vered M. Update from the 4th edition of the World Health organization classification of head and neck tumours: odontogenic and maxillofacial bone tumors. Head Neck Pathol 2017; 11: 68-77.

36. Gultekin SE, Aziz R, Heydt C, Senguven B, Zoller J, Safi AF et al. The landscape of genetic alterations in ameloblastomas relates to clinical features. Virchows Arch. 2018; 472: 807-814.

37. Brown NA, Rolland D, McHugh JB, Weigelin HC, Zhao L, Lim MS et al. Activating FGFR2-RAS-BRAF mutations in ameloblastoma. Clin Canc Res. 2014; 20: 5517-5526.

38. Heikinheimo K, Huhtala JM, Thiel A, Kurppa KJ, Heikinheimo H, Kovac M et al. The mutational profile of unicystic ameloblastoma. J Dent Res. 2019; 98: 54-60.

39. Pereira NB, Pereira KM, Coura BP, Diniz MG, de Castro WH, Gomes CC et al. BRAFV600E mutation in the diagnosis of unicystic ameloblastoma. J Oral Pathol Med. 2016; 45: 780-785.

40. Shi HA, Ng CWB, Kwa CT, Sim QXC. Ameloblastoma: a succinct review of the classification, genetic understanding and novel molecular targeted therapies. Surgeon. 2021; 19 (4): 238-243.